Literature DB >> 8825335

Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.

J Wójcicki1, T Sulikowski, M Wójcicki, M Droździk, B Gawrońska-Szklarz, B Barcew-Wiszniewska, J Skowron, L Rózewicka.   

Abstract

1. An altered functional state of liver due to experimental cholestasis could result in a change in the biotransformation of drugs. The aim of this study was to evaluate an influence of obstructive cholestasis on the pharmacokinetics of phenazone (antipyrine). 2. The investigation was carried out on male rabbits, randomly allocated into two groups: shamoperated and animals with biliary ducts ligation. Phenazone was administered intragastrically as a probe of drug metabolism. 3. Measurements, i.e. laboratory and pharmacodynamic tests, as well as pharmacokinetic assays, were performed before the operation as well as 10-12 days after the bile duct ligation. At the end of the study livers were examined macro- and microscopically and biochemical analysis of the liver microsomes was performed. 4. The measured pharmacokinetic parameters suggested an impaired biotransformation of phenazone in animals with obstructive cholestasis, leading to a slower drug elimination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825335      PMCID: PMC1909376          DOI: 10.1111/j.1476-5381.1996.tb15146.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Determination of cholesterol using o-phthalaldehyde.

Authors:  L L Rudel; M D Morris
Journal:  J Lipid Res       Date:  1973-05       Impact factor: 5.922

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

4.  Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.

Authors:  G W Hepner; E S Vesell
Journal:  Am J Dig Dis       Date:  1975-01

5.  Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition.

Authors:  G W Hepner; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

Review 6.  [The use of the antipyrine test for studying microsomal drug oxidation].

Authors:  A P Viktorov; A T Rybak
Journal:  Farmakol Toksikol       Date:  1990 Jan-Feb

7.  Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity.

Authors:  S Imaoka; Y Imai; T Shimada; Y Funae
Journal:  Biochemistry       Date:  1992-07-07       Impact factor: 3.162

Review 8.  Metronidazole and antipyrine as probes for the study of foreign compound metabolism.

Authors:  S Loft
Journal:  Pharmacol Toxicol       Date:  1990

9.  Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function?

Authors:  J Reichen; J T Buters; Z Sojcic; F J Roos
Journal:  Experientia       Date:  1992-05-15

10.  Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.

Authors:  J T Buters; T Zysset; J Reichen
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.